Jco precision oncology.

DOI: 10.1200/PO.20.00429 JCO Precision Oncology no. 5 (2021) 1001-1012. Published online June 10, 2021. PMID: 34994626. Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model Eryn Dow, BSc, BMBS 1, 2. x. Eryn Dow. Search for articles by this author ...WebThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier MedicinesThe actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of …WebOncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions. PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS We conducted a retrospective multicenter study to identify patients with advanced prostate cancer who harbored somatic loss-of-function CDK12 ...

This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019

DOI: 10.1200/PO.19.00339 JCO Precision Oncology no. 4 (2020) 239-243. Published online March 27, 2020. PMID: 35050735. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA Assay David J. Einstein, MD 1. x. David J. Einstein. Search for articles by this author ...

Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with …WebAs such, scientific outlets in general, and JCO Precision Oncology in particular, owe an immense debt of gratitude to our volunteer peer reviewers. JCO PO strives to provide the highest quality peer review, so in recognition of Peer Review Week 2023 and its theme of Peer Review and The Future of Publishing, ...Oct 31, 2022 · PURPOSE To facilitate implementation of precision medicine in clinical management of cancer, the European Society of Medical Oncology proposed in 2018 a new scale to harmonize and standardize the reporting and interpretation of clinically relevant genomics data (ESMO Scale of Actionability of molecular Targets [ESCAT]). This study aims to characterize the clinical impact of matching targetable ... DOI: 10.1200/PO.22.00342 JCO Precision Oncology no. 7 (2023) e2200342. Published online January 12, 2023. PMID: 36634297 Programmatic …JCO Precision Oncology, 2022 Aug 11. PMID: 35952319; Storrs EP, Usmani A, Chati P, Sloan I, Krasnick BA, Babbra R, Harris PK, Qaium F, Chatterjee D, Wetzel C ...

DOI: 10.1200/PO.18.00299 JCO Precision Oncology - published online April 25, 2019 PMID: 32914040 Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study Tareq Al Baghdadi, MD 1. x. Tareq Al Baghdadi. Search for articles by this author ...Web

DOI: 10.1200/PO.20.00436 JCO Precision Oncology no. 5 (2021) 744-750. Published online May 3, 2021. Published online May 3, 2021. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case ReportSep 13, 2017 · The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ... This is the context motivating the publication by Stetson et al 10 in JCO Precision Oncology. The authors sent aliquots of plasma to four commercial Clinical Laboratory Improvement Amendments–certified laboratories for plasma NGS and compared this to NGS performed on matched tumor and normal tissue at Foundation Medicine. …JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer.Jan 27, 2022 · This author is an Associate Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Ciitizen Corporation, Clariifi, Guidance Genomics. Consulting or Advisory Role: Roche, Roche/Genentech. Speakers' Bureau: Genentech

An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. Le Tourneau et al. Published online: August 8, 2022.DOI: 10.1200/JCO.21.02112 Journal of Clinical Oncology - published online before print January 25, 2022 PMID: ... Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO …DOI: 10.1200/PO.19.00297 JCO Precision Oncology no. 4 (2020) 170-175. Published online March 6, 2020. Published online March 6, 2020. Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and AgesDOI: 10.1200/PO.21.00210 JCO Precision Oncology no. 5 (2021) 1530-1539. Published online September 29, 2021. Published online September 29, 2021. Molecular Tumor Board Review and Improved Overall Survival in …WebDOI: 10.1200/PO.20.00495 JCO Precision Oncology no. 5 (2021) 1122-1132. Published online July 9, 2021. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review Kara L. Larson, PhD …WebJCO PO is a peerreviewed onlineonly articlebased journal publishing original research reports opinions and reviews that advance the science and practice of precision oncology and define genomics and other biomarkerdriven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...WebCHASTEPA metro station (2nd station), SCHOOL #303. A reliable partner for everyone who cares about their health. We offer a wide range of services, ranging from laboratory and …

By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ...

6 Oct 2022 ... Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precis Oncol 2017, PO.PURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 insertion mutations are emerging as a distinct molecular subtype with expanding therapeutic options. We describe the molecular epidemiology and genomic features of …WebThe field of behavioral economics recognizes that humans make decisions within the constraints of bounded rationality because of time and cognitive limits such as those observed with precision oncology. 1 This results in the use of heuristics (such as race), which may in turn increase individuals' reliance on cognitive biases (including …This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …Aug 5, 2021 · DOI: 10.1200/PO.20.00532 JCO Precision Oncology no. 5 (2021) 1241-1249. Published online August 5, 2021. Published online August 5, 2021. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling DOI: 10.1200/PO.18.00356 JCO Precision Oncology - published online May 16, 2019 Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model Nathan A. Pennell, MD, PhD 1. x. Nathan A. Pennell. Search for articles …This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: TP Therapeutics, Nuvalent, Inc. Honoraria: Natera.

DOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812

DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017Web

28 Mar 2023 ... Dr Matteo Lambertini speaks to ecancer about the present and future of precision oncology in breast cancer. He begins by highlighting the ...DOI: 10.1200/PO.20.00417 JCO Precision Oncology no. 5 (2021) 450-454. Published online February 26, 2021. PMID: 34994601. NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets Elke Pfaff, MD. x. Elke Pfaff. Search for articles by this author ...Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017 PURPOSE To develop and validate a cross-ancestry integrated risk score (caIRS) that combines a cross-ancestry polygenic risk score (caPRS) with a clinical estimator for breast cancer (BC) risk. We hypothesized that the caIRS is a better predictor of BC risk than clinical risk factors across diverse ancestry groups. METHODS We used diverse retrospective cohort data with longitudinal follow-up ...DOI: 10.1200/PO.18.00028 JCO Precision Oncology - published online October 19, 2018WebDOI: 10.1200/PO.23.00044 JCO Precision Oncology no. 7 (2023) e2300044. Published online June 29, 2023. PMID: 37384864. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration Christine N. Bailey, MPH 1. x. Christine N. Bailey. Search for articles …WebIan F Tannock's Comment1 summarises the experience to date in precision medicine for children with cancer2–4 and its parallel with the adult experience. The …DOI: 10.1200/PO.21.00463 JCO Precision Oncology no. 6 (2022) e2100463. Published online April 27, 2022. Published online April 27, 2022. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast …

Jun 27, 2017 · Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified. Methods We queried a commercial laboratory database of ... Key Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ...The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...Instagram:https://instagram. biggest stock winnerstop losers stocks todayplaces to buy silver onlinecmpy DOI: 10.1200/PO.22.00294 JCO Precision Oncology no. 7 (2023) e2200294. Published online January 12, 2023. PMID: 36634300. Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States ... 5g stockstqqq ex dividend date DOI: 10.1200/PO.20.00321 JCO Precision Oncology no. 5 (2021) 510-524. Published online March 19, 2021. Published online March 19, 2021. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy wti futures price DOI: 10.1200/PO.21.00181 JCO Precision Oncology no. 6 (2022) e2100181. Published online March 9, 2022. PMID: 35263168. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors Pashtoon M. Kasi, MD, MS 1. x. Pashtoon M. Kasi. Search for articles by …WebKey Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ... Stage 4 is the final stage of most cancers that have spread to other areas of the body, states the American Society of Clinical Oncology. Cancer stages are usually determined by the size, growth and spread of the cancer.